Abivas grabs funding
Abivas, a French clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, has secured 12 million euros in funding. The investor was Sofinnova Partners.
12 July 2019•1 min read
